BTIG raised the firm’s price target on Guardant Health (GH) to $140 from $100 and keeps a Buy rating on the shares as part of a broader research note reviewing 2025 for Diagnostics and Tools. The firm also named the stock its 2026 Top Pick. Guardant has many catalysts – Shield CRC, Shield MCED, G360 tissue, Reveal, ACS guidelines and in 2026, and investor sentiment is solid again, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health price target raised to $135 from $100 at Citi
- Guardant Health assumed with an Overweight at Morgan Stanley
- Private Markets: Prediction market platform Kalshi secures $300M
- Guardant Health price target raised to $120 from $90 at Piper Sandler
- Guardant Health Completes $402.5M Convertible Notes Offering